PHOENIX, March 31, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, of urology, neurology and orthopedics, today announced the signing of a framework collaboration agreement with the University of Miami to accelerate the development of the company’s ImmCelz® supercharged autologous immunotherapy platform.
ImmCelz®, which is protected by trade secrets and published US patents, uses adult stem cells from qualified donors to impart specific properties to the patient’s immune cells. Once the cells harvested from the patient have been incubated with the company’s cell-free reprogramming “cocktail”, the cells are returned to the patient. These “supercharged” cells subsequently “educate” other cells of the immune system to stop attacking the body, while preserving the ability to attack foreign pathogens.
“This valuable partnership with the University of Miami accelerates the development of our ImmCelz® platform,” said Timothy Warbington, President and Chief Executive Officer of the Company. “Under the direction of Drs. Camille Ricordi and Giacomo Lanzoni at the cGMP Advanced Human Cell and Biologics Manufacturing Facility at the Diabetes Research Institute Cell Transplant Center, University of Miami Miller School of Medicine, we will continue to optimize the platform and generate the data needed to advance our therapies through clinical trials. »
“Dr. Lanzoni and I are excited to extend our relationship with Tim and the leadership team at Creative Medical Technology to advance the ImmCelz® platform,” said Dr. Ricordi. “As previously announced, we have already seen early success, suggesting the ability of ImmCelz® to achieve superior results in a preclinical phase, in vitro model system that should lend itself to safe, scalable, and rapid clinical translation. »
“For integration into this framework collaboration agreement, a project proposal and research budget have been submitted by the team of the University of Miami and accepted by the Company for the purpose of immediately commencing further research. We intend to disclose relevant results as appropriate,” Warbington added.
The company plans to advance multiple indications for ImmCelz® beginning with stroke, which is currently under review by the FDA. After gaining approval to proceed with clinical trials in stroke, the company plans to accelerate additional therapies under the ImmCelz® umbrella, including for type I diabetes, heart disease, liver disease and kidney disease.
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics. For more information about the company, please visit www.creativemedicaltechnology.com.
This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
SOURCE Creative Medical Technology Holdings, Inc.